User: Guest  Login
Title:

Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis.

Document type:
Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Article
Author(s):
Oldhoff, JM; Darsow, U; Werfel, T; Katzer, K; Wulf, A; Laifaoui, J; Hijnen, DJ; Plötz, S; Knol, EF; Kapp, A; Bruijnzeel-Koomen, CA; Ring, J; de Bruin-Weller, MS
Abstract:
BACKGROUND: Eosinophils may play an important role in the pathogenesis of atopic dermatitis (AD). Interleukin-5 is essential for eosinophil growth, differentiation and migration. A monoclonal antibody to human interleukin-5 (mepolizumab) was developed for atopic diseases. This study was designed to study the effect of mepolizumab in AD. METHODS: Two single doses of 750 mg mepolizumab, given 1 week apart, were studied in patients with moderate to severe AD using a randomized, placebo-controlled parallel group design. The primary endpoint of 'success' to treatment was defined as the percentage of patients with at least 'marked improvement' after 2 weeks as assessed by the Physician's Global Assessment of Improvement (PGA). Furthermore, SCORing AD (SCORAD), pruritus scoring, number of blood eosinophils and serum thymus and activation-regulated chemokine (TARC) values served as secondary endpoints. Fluticasone propionate cream 0.05%, once daily could be used as rescue medication from day 16 if no improvement was recorded. RESULTS: Eighteen patients received mepolizumab and 22 placebo treatment. Peripheral blood eosinophil numbers were significantly reduced in the treatment group compared with placebo (P < 0.05). No clinical success was reached by PGA assessment (P = 0.115), SCORAD (P = 0.293), pruritus scoring and TARC values in the mepolizumab-treated group compared with placebo. However, modest improvement (<50% improvement) assessed by PGA was scored significantly more in the mepolizumab-treated group compared with placebo (P < 0.05). CONCLUSION: Two single doses of 750 mg mepolizumab did not result in clinical success in patients with AD, despite a significant decrease in peripheral blood eosinophils.
Journal title abbreviation:
Allergy
Year:
2005
Journal volume:
60
Journal issue:
5
Pages contribution:
693-6
Language:
eng
Fulltext / DOI:
doi:10.1111/j.1398-9995.2005.00791.x
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/15813818
Print-ISSN:
0105-4538
TUM Institution:
Klinik und Poliklinik für Dermatologie und Allergologie
 BibTeX